Seeking first-in-class glory, Roche enlists biotech partner that prides itself on cracking 'undruggable' targets
Roche is on the hunt for some first-in-class projects — and, with the help of a new partner, it’s starting from scratch.
The pharma giant has tapped PhoreMost, a small biotech working out of Cambridge, UK, for a target discovery pact in which PhoreMost will deploy its screening platform toward certain disease-relevant pathways in hematology and immunology selected by Roche.
Once PhoreMost identifies those targets, Roche will take over to further validate and characterize them.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.